Clinical Trial

Prospective Validation of a Pharmacological Biomarker for Low-Dose Rituximab in Rheumatoid Arthritis

Study acronym: PROLOD-RA
Recruiting
View on ClinicalTrials.gov →
Summary
Evaluation of the prediction of clinical response to rituximab at a dose of 1000 mg once using a pharmacological model including several pharmacokinetic and pharmacodynamic parameters.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-10; most recent amendment 2026-04-29.
Status change: Not Yet Recruiting → Recruiting 2026-04-29
Trial Details
NCT Number NCT06933134
Lead Sponsor University Hospital, Tours
Conditions Rheumatoid Arthritis (RA)
Enrollment 30 participants
Start Date 2026-04-23
Primary Completion 2028-11 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2026-04-30